<DOC>
	<DOCNO>NCT01126424</DOCNO>
	<brief_summary>The purpose compare solifenacin oxybutynin inactive tablet assess potential effect mental ability .</brief_summary>
	<brief_title>A Study Compare Two Medications With Inactive Medication Look Effect Person 's Mental Ability</brief_title>
	<detailed_description>All subject receive intervention course study . Subjects complete 21-day washout period treatment period follow last treatment period .</detailed_description>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<mesh_term>Oxybutynin</mesh_term>
	<mesh_term>Mandelic Acids</mesh_term>
	<criteria>The subject mild cognitive impairment determine minimental state examination ( MMSE ) ≥ grade 24 The subject conform Stockholm criterion mild cognitive impairment assess investigator The subject body mass index ( BMI ) 18.0 30.0 kg/m2 inclusive The subject available complete study The subject moderate severe cognitive impairment determine MMSE criterion screen , ≤ grade 23 The subject depression determine Geriatric Depression Scale ( GDS ) short form ≥ 5 screen The subject history urinary retention , severe gastrointestinal obstruction ( include paralytic ileus intestinal atony toxic megacolon severe ulcerative colitis ) , myasthenia gravis , uncontrolled narrow angle glaucoma shallow anterior chamber deem risk condition The subject undergoing hemodialysis severe renal impairment moderate hepatic impairment treatment potent CYP3A4 inhibitor , e.g . Ketoconazole The subject uncontrolled diabetes mellitus The subject positive prestudy hepatitis B surface antigen , hepatitis C antibody HIV result time screen The subject history drug / alcohol abuse time screen The subject average weekly alcohol intake great 21 unit ( male ) 14 unit ( female ) within ≤ 3 month prior screen ( 1 unit 270cc beer , 40cc spirit 125cc wine ) The subject history smoking 10 cigarette ( equivalent amount tobacco ) per day within ≤ 3 month prior screen The subject history know suspected hypersensitivity solifenacin succinate , oxybutynin hydrochloride , anticholinergic lactose , component dosage form The subject take unstable dos prescribe medication within ≤ 1 month prior screen overthecounter medicine ( include vitamin herbal remedy ) within 48 hour prior first study day , opinion Investigator , interfere study procedure compromise safety The subject currently dose medication ( ) intend treat overactive bladder symptom history nondrug treatment intend treat overactive bladder symptom within ≤ 3 month prior screen The subject clinically significant abnormality follow Investigator review physical examination The subject clinically significant abnormality follow Investigator 's review ECG The subject mobility impairment precludes assessment postural stability The subject clinically significant abnormal heart rate blood pressure measurement , screen visit ( dBP &gt; 90mmHg , sBP &gt; 160mmHg HR &lt; 40bpm &gt; 100bpm ) The subject clinically significant abnormality follow Investigator 's review biochemistry &amp; hematology result , opinion Investigator , contraindicate participation The subject donate blood plasma within ≤ 3 month prior screen 500ml 1 unit blood plasma within ≤ 6 month prior screen The subject , may find difficult adhere provision treatment observation specify protocol The subject participate clinical study within ≤ 3 month prior screen The subject clinical condition , diagnosis , symptomatology ongoing investigation , , contraindicate participation The subject employee Astellas Pharma , Cognitive Drug Research , third party relate study site</criteria>
	<gender>All</gender>
	<minimum_age>75 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Anti-muscarinics</keyword>
	<keyword>Anti-cholinergics</keyword>
	<keyword>Cognition</keyword>
	<keyword>Solifenacin</keyword>
</DOC>